Overview

Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the influence of sirolimus on outcome after OLT for HCC exceeding Milan criteria.
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Everolimus
Sirolimus